 |
 |
Merck drops late-stage Parkinson's drug FINANCIAL TIMES Updated: 1:40 p.m. ET June 23, 2006 Shares in Merck dropped on Friday after the German pharmaceuticals company said it was ending the development of Sarizotan, an experimental treatment for Parkinson's disease, after it failed late-stage clinical trials. The failure is a setback for the family-controlled company, as the drug had been expected to eventually generate annual sales of as much as €250m ($314.3m) had it reached the market. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn